Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 32 studies | 44% ± 17% | |
oligodendrocyte | 11 studies | 34% ± 12% | |
glutamatergic neuron | 10 studies | 38% ± 26% | |
capillary endothelial cell | 9 studies | 23% ± 8% | |
pericyte | 9 studies | 35% ± 19% | |
oligodendrocyte precursor cell | 8 studies | 27% ± 8% | |
fibroblast | 8 studies | 27% ± 6% | |
retinal cone cell | 7 studies | 40% ± 25% | |
adipocyte | 7 studies | 24% ± 8% | |
GABAergic neuron | 7 studies | 43% ± 22% | |
endothelial cell of lymphatic vessel | 6 studies | 38% ± 14% | |
neuron | 5 studies | 40% ± 18% | |
endothelial cell of artery | 5 studies | 25% ± 9% | |
interneuron | 5 studies | 40% ± 20% | |
vein endothelial cell | 5 studies | 41% ± 26% | |
endothelial cell of vascular tree | 5 studies | 40% ± 24% | |
smooth muscle cell | 5 studies | 23% ± 6% | |
granule cell | 4 studies | 22% ± 3% | |
retinal ganglion cell | 4 studies | 38% ± 20% | |
Mueller cell | 4 studies | 39% ± 13% | |
astrocyte | 4 studies | 39% ± 18% | |
retinal rod cell | 4 studies | 57% ± 28% | |
cholangiocyte | 3 studies | 45% ± 18% | |
endothelial cell of sinusoid | 3 studies | 33% ± 10% | |
glomerular endothelial cell | 3 studies | 26% ± 2% | |
GABAergic interneuron | 3 studies | 31% ± 13% | |
hepatocyte | 3 studies | 56% ± 20% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 100% | 5448.56 | 89 / 89 | 100% | 49.86 | 897 / 901 |
breast | 100% | 5822.99 | 459 / 459 | 98% | 21.36 | 1099 / 1118 |
prostate | 100% | 4797.65 | 245 / 245 | 98% | 15.88 | 493 / 502 |
liver | 100% | 3536.74 | 226 / 226 | 98% | 19.38 | 398 / 406 |
brain | 100% | 5066.25 | 2629 / 2642 | 96% | 22.39 | 678 / 705 |
pancreas | 100% | 11406.04 | 328 / 328 | 96% | 21.81 | 170 / 178 |
adrenal gland | 100% | 5469.88 | 258 / 258 | 95% | 28.32 | 219 / 230 |
lung | 100% | 4599.65 | 577 / 578 | 94% | 20.35 | 1081 / 1155 |
thymus | 100% | 6687.86 | 653 / 653 | 92% | 20.55 | 555 / 605 |
stomach | 100% | 3069.91 | 359 / 359 | 90% | 14.25 | 258 / 286 |
esophagus | 97% | 3305.06 | 1401 / 1445 | 93% | 20.44 | 170 / 183 |
intestine | 100% | 4515.99 | 963 / 966 | 90% | 13.94 | 475 / 527 |
ovary | 100% | 3112.86 | 180 / 180 | 83% | 10.45 | 359 / 430 |
skin | 91% | 2336.36 | 1643 / 1809 | 90% | 24.14 | 425 / 472 |
uterus | 100% | 4986.23 | 170 / 170 | 74% | 10.48 | 338 / 459 |
bladder | 100% | 7113.00 | 21 / 21 | 73% | 11.07 | 370 / 504 |
adipose | 100% | 5820.78 | 1204 / 1204 | 0% | 0 | 0 / 0 |
muscle | 100% | 5864.76 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 8375.60 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4449.35 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 100% | 4348.22 | 859 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 89% | 13.66 | 40 / 45 |
eye | 0% | 0 | 0 / 0 | 73% | 7.72 | 58 / 80 |
peripheral blood | 54% | 2898.10 | 499 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 10% | 0.57 | 3 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0030178 | Biological process | negative regulation of Wnt signaling pathway |
GO_0010467 | Biological process | gene expression |
GO_0030949 | Biological process | positive regulation of vascular endothelial growth factor receptor signaling pathway |
GO_0070371 | Biological process | ERK1 and ERK2 cascade |
GO_0008286 | Biological process | insulin receptor signaling pathway |
GO_0120162 | Biological process | positive regulation of cold-induced thermogenesis |
GO_0046627 | Biological process | negative regulation of insulin receptor signaling pathway |
GO_1904738 | Biological process | vascular associated smooth muscle cell migration |
GO_0046325 | Biological process | negative regulation of glucose import |
GO_0042326 | Biological process | negative regulation of phosphorylation |
GO_0048009 | Biological process | insulin-like growth factor receptor signaling pathway |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005829 | Cellular component | cytosol |
GO_0005886 | Cellular component | plasma membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0005158 | Molecular function | insulin receptor binding |
GO_0030159 | Molecular function | signaling receptor complex adaptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | GRB10 |
Protein name | Growth factor receptor-bound protein 10 Growth factor receptor bound protein 10 Growth factor receptor-bound protein 10 (GRB10 adapter protein) (Insulin receptor-binding protein Grb-IR) Uncharacterized protein GRB10 |
Synonyms | KIAA0207 GRBIR |
Description | FUNCTION: Adapter protein which modulates coupling of a number of cell surface receptor kinases with specific signaling pathways. Binds to, and suppress signals from, activated receptors tyrosine kinases, including the insulin (INSR) and insulin-like growth factor (IGF1R) receptors. The inhibitory effect can be achieved by 2 mechanisms: interference with the signaling pathway and increased receptor degradation. Delays and reduces AKT1 phosphorylation in response to insulin stimulation. Blocks association between INSR and IRS1 and IRS2 and prevents insulin-stimulated IRS1 and IRS2 tyrosine phosphorylation. Recruits NEDD4 to IGF1R, leading to IGF1R ubiquitination, increased internalization and degradation by both the proteasomal and lysosomal pathways. May play a role in mediating insulin-stimulated ubiquitination of INSR, leading to proteasomal degradation. Negatively regulates Wnt signaling by interacting with LRP6 intracellular portion and interfering with the binding of AXIN1 to LRP6. Positive regulator of the KDR/VEGFR-2 signaling pathway. May inhibit NEDD4-mediated degradation of KDR/VEGFR-2. . |
Accessions | ENST00000401949.6 [Q13322-1] A0A2R8YCL1 ENST00000643299.1 [Q13322-3] Q75MT1 ENST00000428711.1 H7C3B9 ENST00000406641.5 [Q13322-3] ENST00000644879.1 ENST00000439044 ENST00000644769.1 ENST00000335866.7 [Q13322-3] ENST00000398812.6 [Q13322-1] Q75M93 ENST00000403097.6 [Q13322-3] A0A2R8Y6Q4 ENST00000398810.6 [Q13322-3] ENST00000357271.9 [Q13322-2] ENST00000402497.6 [Q13322-3] ENST00000645075.2 [Q13322-3] ENST00000407526.6 [Q13322-3] C9JTW6 ENST00000402578.5 [Q13322-3] Q13322 |